Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

Arthritis and Rheumatism

Volumn 58, Issue 5, 2008, Pages 1496-1504

  Lovell, Daniel J ^a   Reiff, Andreas ^b   Ilowite, Norman T ^c   Wallace, Carol A ^d   Chon, Yun ^e   Lin, Shao Lee ^e   Baumgartner, Scott W ^e   Giannini, Edward H ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEMYELINATING DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; LOW DRUG DOSE; LUPUS VULGARIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; OPEN STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 43949143169     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23427     Document Type: Article

References (25)

1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002;29:1520-30.
2. Gare A. Juvenile arthritis - who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999;17:367-74.
3. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
4. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41:1428-35.
5. Ilowite, NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109:109-15.
6. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84.
7. Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003;33:1-18.
8. Carrasco R, Smith JA, Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 2004;6:137-46.
9. Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis 2006;64:72-6.
10. Munro JE, Murray KJ. Advances in paediatric rheumatology: beyond NSAIDs and joint replacement. J Paediatr Child Health 2004;40:161-9.
11. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
12. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005;52:548-53.
13. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Norton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
14. Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol 1992;33:6-10.
15. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
16. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al, for the Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: results from an on-going multicenter, open-label, extended treatment trial. Arthritis Rheum 2003;48:218-26.
17. Lovell DJ, Reiff A, Jones OY, Schneider R, Norton J, Stein LD, et al, for the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
18. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
19. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
20. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
21. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64: 1557-62.
22. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
23. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10.
24. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
25. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-9.